An Early Phase 1 interventional study of ACG102 Injection in Refractory Active Systemic Lupus Erythematosus, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — 8 open to participants now, 8 under way, none of them phase 3. Lupus Erythematosus, Systemic · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.
Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, this one is the 5th largest by planned enrollment, is one of 5 that started in 2026, is one of 7 in phase 1, and was the 11th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →8 of the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology are open now, in 1 country. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–70
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–65
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–60
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–60
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 1
First in 2024; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 13 is below the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 12 across the 11 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology is the lead sponsor of 183 studies on the registry; 146 are open to participants now.
6 of the studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07470151Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases | 2026-11 |
| NCT06400537Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus | 2026-12 |
| NCT07031713Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySafety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE | 2026-12-31 |
| NCT07749430Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Clinical Study of ACG102 Injection in Patients With Refractory Active Systemic Lupus Erythematosus | 2027-01-30 |
| NCT07339332Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyA Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 11 studies in Lupus Erythematosus, Systemic by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of ACG102 administered via intravenous injection in patients with refractory active systemic lupus erythematosus (SLE)
A first-in-human, open label study to evaluate safety and tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of multiple ascending dose ACG102 intravenously administered to adult participants with refractory active systemic lupus erythematosus (SLE)
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Multiple escalating intravenous doses of ACG102 administered on pre-specified days to adult patients with refractory active SLE. Dose levels and schedules may be adjusted based on emerging safety, tolerability, and PK/PD data, followed by a safety and efficacy follow-up period.
Drug: ACG102 Injection
All enrolled participants will receive multiple intravenous infusions of ACG102 at the dose level assigned to their cohort. Dose levels and dosing schedules may be adjusted based on emerging safety, tolerability, and PK/PD data.
Incidence of dose-limiting toxicities (DLTs)
Number and proportion of participants experiencing DLT. A DLT is defined as any treatment-emergent adverse event (TEAE) occurring within the 21-day DLT evaluation period post-infusion that meets protocol-specified criteria, graded per NCI CTCAE v5.0 and ASTCT consensus criteria for CRS and ICANS, and is considered at least possibly related to the study intervention
Time frame: Within 21 days after first dose
Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Percentage of participants experiencing TEAEs, SAEs, and Adverse Events of Special Interest (AESIs) graded per NCI CTCAE v5.0 and ASTCT consensus criteria
Time frame: From first dose through Week 52
Incidence of Treatment-Emergent Clinical Laboratory Abnormalities
Number of participants with clinically significant shifts from baseline in safety laboratory assessments (hematology, liver enzymes, coagulation, and vital sign)
Time frame: Up to 52 weeks post first dose
Change from baseline in SLE disease activity scores
Change from baseline will be calculated as the score at each post-baseline visit minus the score at baseline in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K)
Time frame: baseline and up to Week 52 post first dose
Change from Baseline in BILAG-2004 Score
Change from baseline will be calculated as the total score at each post-baseline visit minus the score at baseline of the British Isles Lupus Assessment Group 2004 Index (BILAG-2004)
Time frame: pre-dose and up to 52 weeks post the first dose
Change from Baseline in Physician's Global Assessment (PGA) Score
Change from baseline will be calculated as the score at each post-baseline visit minus the score at baseline of PGA score
Time frame: pre-dose and up to 52 weeks post first dose
Composite efficacy response rates
Proportion of participants achieving the SLE Responder Index-4 (SRI-4) response
Time frame: baseline and up to Week 52 post first dose
Composite efficacy response rates
Proportion of participants achieving Lupus Low Disease Activity State (LLDAS)
Time frame: baseline and up to Week 52 post first dose
Composite efficacy response rates
Proportion of participants achieving the Definition Of Remission In SLE (DORIS).
Time frame: Baseline and up to Week 52 post first dose
Change from baseline in SF-36 score
Change from baseline in 36-Item Short-Form Health Survey (SF-36) score.
Time frame: baseline and up to Week 52 post first dose
Change from baseline in renal parameters
Urine protein will be quantified from a 24-hour urine collection at each scheduled visit, expressed in grams per 24 hours (g/24h). Change from baseline will be calculated as the value at each post-baseline visit minus the value at baseline
Time frame: Baseline and up to Week 52 post first dose
Change from baseline in renal parameters
Change from Baseline in Urine Protein-to-Creatinine Ratio (UPCR).Change from baseline will be calculated as the value at each post-baseline visit minus the value at baseline.
Time frame: Baseline and up to Week 52 post first dose
Change from baseline in renal parameters
Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) by CKD-EPI;Change from baseline will be calculated as the value at each post-baseline visit minus the value at baseline.
Time frame: baseline and up to Week 52 post first dose
Change from baseline in renal parameters
Proportion of participants with baseline proteinuria \>0.5 g/24h achieving proteinuria negativity.
Time frame: Baseline and up to Week 52 post first dose
Pharmacokinetic profiling
Quantification of Target mRNA Expression Levels in Biological Samples via RT-qPCR.
Time frame: Baseline and up to 24 weeks post first dose
Pharmacokinetics measurement
Bioanalytical Quantification of Cationic Lipids and Major Metabolites using LC/MS
Time frame: baseline and up to 24 weeks post first dose
Pharmacodynamic Profiling
Serum concentrations of the TCE protein will be evaluated using a validated Enzyme-Linked Immunosorbent Assay (ELISA)
Time frame: Baseline and up to 24 weeks post first dose
Pharmacodynamic biomarkers
Changes from baseline in serum IgG, IgM, IgA, anti-dsDNA antibodies, complement C3, and complement C4.
Time frame: Baseline and up to 52 weeks post first dose
Immunogenicity
Percentage of participants who develop treatment-induced or treatment-enhanced ADAs and subsequent NAbs against ACG102 as determined by validated immunoassays.
Time frame: Baseline and up to 52 weeks post first dose
Immunogenicity
Percentage of participants with detectable antibodies directed against the PEG component of the formulation, measured via validated serum assays.
Time frame: Baseline and up to 52 weeks post first dose
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jan 2027, 4 months later.
Of 147 phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's planned 4 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology →